417.21
price down icon1.23%   -5.18
after-market Dopo l'orario di chiusura: 417.05 -0.16 -0.04%
loading
Precedente Chiudi:
$422.39
Aprire:
$418.02
Volume 24 ore:
1.32M
Relative Volume:
0.73
Capitalizzazione di mercato:
$106.97B
Reddito:
$11.39B
Utile/perdita netta:
$3.64B
Rapporto P/E:
29.82
EPS:
13.9904
Flusso di cassa netto:
$3.50B
1 W Prestazione:
-2.16%
1M Prestazione:
+5.54%
6M Prestazione:
-17.14%
1 anno Prestazione:
-11.30%
Intervallo 1D:
Value
$415.77
$422.98
Intervallo di 1 settimana:
Value
$415.77
$432.76
Portata 52W:
Value
$362.50
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
Nome
Vertex Pharmaceuticals Inc
Name
Telefono
(617) 341-6393
Name
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Name
Dipendente
6,100
Name
Cinguettio
@VertexPharma
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
VRTX's Discussions on Twitter

Confronta VRTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
417.21 108.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
652.91 69.37B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.59 62.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
821.97 51.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.95 34.94B 398.11M -1.03B -868.57M -5.7032

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-09-25 Aggiornamento Leerink Partners Market Perform → Outperform
2025-09-03 Iniziato Raymond James Mkt Perform
2025-08-06 Aggiornamento Wells Fargo Equal Weight → Overweight
2025-05-07 Downgrade Wolfe Research Outperform → Peer Perform
2025-05-06 Downgrade Leerink Partners Outperform → Market Perform
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-12 Aggiornamento Canaccord Genuity Sell → Hold
2025-02-11 Aggiornamento Canaccord Genuity Sell → Hold
2025-01-30 Downgrade Wells Fargo Overweight → Equal Weight
2024-12-20 Reiterato H.C. Wainwright Buy
2024-12-19 Downgrade Oppenheimer Outperform → Perform
2024-12-09 Aggiornamento Jefferies Hold → Buy
2024-11-14 Iniziato Citigroup Buy
2024-10-16 Iniziato Scotiabank Sector Perform
2024-10-10 Ripresa Raymond James Mkt Perform
2024-08-05 Downgrade Barclays Overweight → Equal Weight
2024-06-27 Iniziato Redburn Atlantic Buy
2024-04-11 Aggiornamento Evercore ISI In-line → Outperform
2024-02-15 Iniziato Wolfe Research Outperform
2024-02-06 Downgrade Evercore ISI Outperform → In-line
2024-02-02 Downgrade Bernstein Outperform → Mkt Perform
2024-01-31 Downgrade Maxim Group Buy → Hold
2024-01-31 Downgrade Robert W. Baird Neutral → Underperform
2024-01-24 Downgrade Canaccord Genuity Hold → Sell
2023-12-14 Reiterato RBC Capital Mkts Sector Perform
2023-05-30 Iniziato William Blair Outperform
2023-05-04 Ripresa Piper Sandler Overweight
2023-03-21 Iniziato Bernstein Outperform
2023-01-18 Iniziato Canaccord Genuity Hold
2023-01-17 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-12-19 Downgrade Jefferies Buy → Hold
2022-07-13 Iniziato Cantor Fitzgerald Overweight
2022-06-01 Aggiornamento Maxim Group Hold → Buy
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-05-06 Downgrade Robert W. Baird Outperform → Neutral
2022-05-03 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-02-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-01-27 Reiterato JP Morgan Overweight
2022-01-27 Reiterato Morgan Stanley Underweight
2022-01-27 Reiterato RBC Capital Mkts Outperform
2022-01-27 Reiterato Stifel Hold
2022-01-27 Reiterato Wolfe Research Outperform
2022-01-20 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-12-09 Iniziato Wells Fargo Overweight
2021-11-19 Iniziato BMO Capital Markets Market Perform
2021-11-19 Downgrade Piper Sandler Overweight → Neutral
2021-09-09 Downgrade Stifel Buy → Hold
2021-09-07 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-07-20 Downgrade SVB Leerink Mkt Perform → Underperform
2021-07-19 Ripresa Wolfe Research Outperform
2021-07-01 Iniziato Raymond James Mkt Perform
2021-06-11 Downgrade Daiwa Securities Outperform → Neutral
2021-02-23 Aggiornamento Robert W. Baird Neutral → Outperform
2021-02-02 Reiterato H.C. Wainwright Buy
2020-12-30 Iniziato Daiwa Securities Outperform
2020-11-30 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2020-11-20 Iniziato Bernstein Outperform
2020-10-28 Iniziato UBS Buy
2020-07-31 Reiterato H.C. Wainwright Buy
2020-07-08 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-04-30 Reiterato H.C. Wainwright Buy
2020-04-28 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-03-04 Iniziato Barclays Overweight
2020-01-31 Downgrade Robert W. Baird Outperform → Neutral
2019-11-19 Aggiornamento Guggenheim Neutral → Buy
2019-11-12 Iniziato SunTrust Buy
2019-10-17 Ripresa BofA/Merrill Buy
2019-09-03 Aggiornamento Goldman Neutral → Buy
2019-08-01 Downgrade Needham Buy → Hold
2019-05-23 Ripresa Citigroup Buy
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-12 Iniziato Evercore ISI In-line
2019-03-26 Aggiornamento William Blair Mkt Perform → Outperform
2019-03-19 Downgrade SVB Leerink Outperform → Mkt Perform
2019-02-06 Downgrade Maxim Group Buy → Hold
Mostra tutto

Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie

pulisher
05:32 AM

Published on: 2025-10-29 04:32:30 - newser.com

05:32 AM
pulisher
04:42 AM

Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weaknessJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com

04:42 AM
pulisher
04:21 AM

Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryEntry Point & High Conviction Buy Zone Picks - newser.com

04:21 AM
pulisher
02:20 AM

Will Vertex Pharmaceuticals Incorporated benefit from macro trendsPortfolio Gains Summary & Risk Managed Investment Entry Signals - newser.com

02:20 AM
pulisher
01:03 AM

Visual analytics tools that track Vertex Pharmaceuticals Incorporated performance2025 Pullback Review & Capital Efficient Trade Techniques - newser.com

01:03 AM
pulisher
Oct 28, 2025

H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX) - Insider Monkey

Oct 28, 2025
pulisher
Oct 28, 2025

Vertex Pharmaceuticals Stock Rises 8.9% as Pipeline Progress Renews Valuation Debate - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings (VRTX) - Seeking Alpha

Oct 28, 2025
pulisher
Oct 28, 2025

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsPortfolio Gains Summary & Free Safe Entry Trade Signal Reports - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Real time pattern detection on Vertex Pharmaceuticals Incorporated stockTrade Risk Assessment & Daily Entry Point Trade Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

How big funds are accumulating Vertex Pharmaceuticals Incorporated (VX1) stockEarnings Recap Report & AI Driven Stock Reports - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Published on: 2025-10-28 05:03:31 - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Momentum divergence signals in Vertex Pharmaceuticals Incorporated chartPortfolio Update Summary & Pattern Based Trade Signal System - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will Vertex Pharmaceuticals Incorporated bounce back from current supportDay Trade & Free Risk Controlled Daily Trade Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potentialQuarterly Investment Review & Daily Oversold Bounce Ideas - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Using data tools to time your Vertex Pharmaceuticals Incorporated exitForecast Cut & Weekly Consistent Profit Watchlists - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Long term hold vs stop loss in Vertex Pharmaceuticals IncorporatedWeekly Profit Recap & Weekly Watchlist of Top Performers - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

How Vertex Pharmaceuticals Incorporated (VX1) stock compares with top peersMarket Activity Recap & Entry Point Confirmation Signals - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances VX-407 Study for ADPKD - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances Pain Management with Suzetrigine Study - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals’ VX-993 Study: A Potential Game-Changer for Diabetic Neuropathy - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals’ Inaxaplin Study: A Potential Game-Changer in Kidney Disease Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances in DPN Treatment with Suzetrigine Study - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals’ VX-828 Study: A New Hope for Cystic Fibrosis Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances Genetic Research in ADPKD with New Study - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances Phase 3 Study on Suzetrigine for Diabetic Neuropathy Pain - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals’ Suzetrigine Study: A New Frontier in Pain Management - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances in Kidney Disease Treatment with VX-147 Study - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals: Pioneering New Treatments for Kidney Disorder - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals’ VX-880 Study: A Potential Game-Changer for Type 1 Diabetes with Kidney Transplant - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances VX-670 Study for Myotonic Dystrophy Type I - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex to Participate in the UBS Global Healthcare Conference on November 11 - Business Wire

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals’ VX-407 Study: A Potential Game-Changer in Oral Contraceptive Pharmacokinetics - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals’ Promising Cystic Fibrosis Study: A Potential Game-Changer - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex’s VX-880 Study: A Potential Game-Changer for Type 1 Diabetes - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances Cystic Fibrosis Treatment with New Pediatric Study - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances Sickle Cell Disease Treatment with Exa-cel Study - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances VX-670 Study for Myotonic Dystrophy Type 1 - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals Advances with Promising CRISPR Gene-Editing Study - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Will Vertex Pharmaceuticals Incorporated stock beat EPS estimates2025 Price Momentum & Trade Opportunity Analysis - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? - sharewise.com

Oct 27, 2025
pulisher
Oct 27, 2025

Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030 - The Globe and Mail

Oct 27, 2025

Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$652.91
price down icon 0.24%
$481.59
price up icon 1.19%
$821.97
price down icon 1.72%
$166.95
price up icon 1.00%
biotechnology ONC
$314.85
price down icon 0.63%
Capitalizzazione:     |  Volume (24 ore):